OR WAIT null SECS
February 23, 2015
Celltrion announced that its Remicade biosimilar, Rensima, could save France, Italy, and the UK up to €336 million in costs to treat Crohn’s disease.
February 11, 2015
Pfenex announced that it entered into an agreement to partner with Hospira on the development and commercialization of PF582, a biosimilar candidate to Lucentis.
February 02, 2015
Ligand-binding assays are fundamental to characterizing biosimilars.
EMA is under pressure to exert even tighter standards on biosimilars being marketed in Europe.
Market forces may limit the success of CMOs.
January 08, 2015
An FDA expert committee has recommend approval of Zarizio, the first US biosimilar application from Sandoz, setting a milestone for generic biologic drugs and setting the stage for future approvals.
December 19, 2014
FDA has scheduled a public meeting in early January to assess and weigh data on the first United States application for a biosimilar therapy.
October 06, 2014
The total market for biopharmaceuticals in 2013 was $36.8 billion according to Kalorama Information. Meanwhile, Frost & Sullivan estimates that the biosimilars market, which it pegged at just $1.2 billion in 2013, will grow to $23 billion in 2019, or more than 20-fold increase.
August 01, 2014
With a number of branded biologics hanging at the patent cliff, the future looks promising for biosimilars.
To realise the full potential for biosimilars, stakeholders must build a better understanding of biosimilars and to take a comprehensive view of how these important medicines can fit into treatment pathways.